Getting ADHD medication in Israel
August 10, 2026 · View on GitHub
A public, redacted case record of what happened when a patient with a valid, in-date prescription for a controlled stimulant tried to obtain it before travelling abroad, in Jerusalem, between 29 July and 9 August 2026.
It is written from primary material: contemporaneous recordings and transcripts of the pharmacy counter, the email correspondence with the district pharmacist, the acknowledgments and the closure letters from the health fund and the Ministry of Health, and the published procedures the whole thing was supposed to run on.
The medication in question is lisdexamfetamine (Vyvanse) 70 mg, one capsule daily, on a standing prescription of several years, dispensed on a 30-day interval. The trip was 22 days. There were roughly 13 capsules in hand.
The case in ten lines
- A request was filed through the health fund's own app on 29 July, on a
page titled "בקשה לאישור מקדים לתרופה" — request for prior authorisation
for a medication — with flight documents attached, against a 5 August
departure. The Ministry's own published service standard for travel supply is
one week, and that standard was met. (The fund's own page asks two weeks
— for a declaration form the patient was never directed to, on a route its
own eligibility rule excluded him from. Dealt with squarely in
docs/what-the-rules-say.md§A3.) - The request never moved. It sat at "בטיפול" — under treatment — and issued no reference number, no rejection and no redirect.
- At the counter on 3 August, the branch office said the medication could be collected downstairs. Five minutes later the pharmacy in the same building said the opposite, and named a route through the district pharmacist that it said takes "two days to a week".
- On 4 August, the last working day before the flight, the branch office gave a direct number and asked the pharmacist to call. The pharmacy's managing pharmacist refused to make or take that call, refused to dispense, and said on the record: "Right now I have no solution. If you fly next week I have a solution."
- The same afternoon: the Ministry of Health's Jerusalem offices — not admitted past the guard. The district pharmacy office — signage on site confirms it is the right building, not allowed in. Around ten calls over 24 hours to two published numbers, not one answered. The office is published as by appointment only.
- The medication was obtained in the end because a private pharmacy dispensed it lawfully against the valid, in-date prescription. No part of the official system produced a route.
- After departure, the district pharmacist replied in writing — twice. His answer: submit through the dispensing pharmacy; the pharmacy must send the request to me; "there is no need to send further emails." The pharmacy had already refused, and had named him as the reason.
- On 9 August the public complaints commissioner under the National Health Insurance Law closed the file without examining it, on the ground that the remedies asked for were service and administrative rather than an entitlement or a refund.
- On the same day the Ministry's service division closed its own file with the health fund's answer: dispensing of up to 60 days / two months at once has been available for some time where the prescription meets the conditions, with the doctor noting it on the prescription. Tracing that back to its source found תקנה 13(א)(8)(ב) לתקנות הסמים המסוכנים — which sets the figure at 62 days, names ADHD expressly, and has been in force since 3 March 2025.
- Not one person in the chain mentioned that. Not the app, not the branch office, not the managing pharmacist across two refusals, not the district pharmacist across two written replies. A national regulation naming this diagnosis had authorised two months' supply for over a year, and it surfaced in a complaint response four days after the plane left.
That last point is the case. Everything else is detail.
And it generalises. Across nine days, six professional accounts of "the
procedure" were given by six sources, and none of them matched the published
regulations — including the fund's own app, its page for this medicine, and,
when it finally disclosed the two-month route, the Ministry's own closure
letter, which got both the number and the date wrong. The provision can only be
invoked by a prescribing doctor, and appears to have been published nowhere a
prescribing doctor would encounter it. See
docs/findings.md §10.
The finding, stated once
The controls on stimulant medication are legitimate. The access path to their most predictable exception does not exist.
Those two clauses have to be held apart. Arguing that stimulant controls are themselves oppressive converts a strong regulatory complaint into a grievance and hands the respondent an easy answer. This record concedes, explicitly: a 30-day dispensing interval is ordinary and broadly what the international narcotics conventions oblige; routing exceptions through a named regional officer is sound design; requiring a passport and a ticket for travel supply is reasonable.
What is documented here is narrower and harder to answer: a published national procedure exists for exactly this situation, the patient met its published lead time, and it was neither applied nor mentioned — while every office in the chain pointed at another office, in writing.
Travel is not an edge case. Every patient on this medication who leaves the country meets this.
Contents
| Document | What is in it |
|---|---|
docs/timeline.md | Every event, with dates, from the app request to the closure letters |
docs/what-the-rules-say.md | The published procedures — MoH Procedure 155, the gov.il traveller page, the fund's own entitlement page — and where they contradict each other |
docs/findings.md | The systemic findings, each with what supports it and how confident it is |
docs/correspondence.md | The exchange with the district pharmacist, and the official responses, quoted |
docs/counter-record.md | Redacted excerpts from the two recorded counter interactions |
docs/not-a-one-off.md | Why this is the routine state, not one bad week |
docs/outcomes.md | Where each of the six approaches ended, including two closures on the same day |
docs/what-would-fix-it.md | Six remedies, none of which require loosening a single control |
docs/redaction-policy.md | What was removed from this public version, and why |
What this is, and is not
It is a first-person case record, published so that the pattern can be examined by people who were not there — patients, advocacy organisations, regulators, journalists, researchers.
It is not legal advice, and not a guide to obtaining medication. Nothing here should be read as a route to work around a control. Where a control applied, this record says so.
It is not an attack on any individual. Every individual who appears in the
source material — pharmacists, clerks, officials, doctors — has been reduced to
their role. See docs/redaction-policy.md. The
failure documented here is structural: the same conversation happens in the
same building, between the same offices, whoever is standing at the counter
that day.
It is one case. A single patient, a single fund, a single city, a single month. It is offered as a detailed, source-backed data point, not as a survey.
It is written by the patient. I am Daniel Rosehill, an Israeli resident in Jerusalem, diagnosed with ADHD and treated with this medication on a standing prescription for several years. The record is written in the third person because it is meant to be usable by people who were not there — but the account, the recordings and the correspondence are mine, and I am contactable through this repository's issues.
Why it is public
Two reasons.
Because the diagnosis is the expensive part. Working out which procedure applied, which office holds the power, and why every route led back to the counter took days that a person with 48 hours before a flight does not have. That work is written down here so the next patient starts from it rather than rediscovering it.
Because of an irony worth naming. The population subject to this bureaucracy is, by diagnosis, the population that has the most difficulty navigating multi-step administrative processes with no documentation, no reference numbers and no reachable owner. A control regime that can only be satisfied by exceptional persistence is not neutral with respect to the people it applies to.
Contact was made during this episode with Keshev — עמותת קווים ומחשבות, the Israeli ADHD advocacy organisation, whose CEO called back on 4 August and discussed, among other things, applying AI and automation skills to the organisation's advocacy work; a meeting was agreed for after the trip. This record is offered in that spirit — as real-world documentation of procedural failure that an advocacy body can actually use. Keshev has not reviewed, approved or endorsed anything in this repository, and nothing here should be read as their position.
Using this material
Quote it, cite it, reuse it. If you are an advocacy organisation, a journalist or a researcher and you want the underlying detail that is not published here — the full recordings, the unredacted correspondence, the filings — ask. Some of it can be shared on request in ways it cannot be published.
If you have had the same experience, write it down the same way: dates, what was said, who said it by role, what was published at the time, and what you can point at. One case is an anecdote. Twenty documented the same way are a finding.
Licence
Documentation: CC BY 4.0. See LICENSE.
Verified as at 10 August 2026. Where something is inferred rather than confirmed, the text says so.